Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Unigene Laboratories, a provider of design, delivery, manufacture and development of peptide-based therapeutics, has entered into a clinical manufacturing agreement with Cara Therapeutics.
Subscribe to our email newsletter
Under the agreement, Unigene is expected utilize its peptide manufacturing technology to offer clinical supply material for a Phase 3 study of experimental drug CR845, to be conducted by Cara.
CR845 is a peripherally acting kappa opioid agonist being developed as a treatment for both acute and chronic pain.
Unigene president and CEO Ashleigh Palmer said they are pleased to have had early success with Cara via the results of a feasibility study, then to be selected as their partner of choice to manufacture its Phase 1 study clinical trial material, and believe this transaction represents further validation of their oral delivery technology.
"We anticipate additional feasibility studies will be commissioned throughout the remainder of this year," Palmer said.